Market Overview

Bristol-Myers Squibb Says Orencia Approved by EU

Related BMY
Bristol-Myers Squibb's Next 8 Months: What To Expect
Earnings Scheduled For April 28, 2015
Seeking Alpha's Biotech Weekly: A Gilead Victory, Celladon Crumbles, And More (Seeking Alpha)

Bristol-Myers Squibb announced today that the European Commission has granted marketing authorisation for the subcutaneous formulation of ORENCIA ® (abatacept), in combination with methotrexate (MTX), for the treatment of adults with moderate to severe active rheumatoid arthritis (RA).

Posted-In: News FDA


Related Articles (BMY)

Around the Web, We're Loving...